[HTML][HTML] Biological aging processes underlying cognitive decline and neurodegenerative disease
MM Gonzales, VR Garbarino, E Pollet… - The Journal of …, 2022 - Am Soc Clin Investig
Alzheimer's disease and related dementias (ADRD) are among the top contributors to
disability and mortality in later life. As with many chronic conditions, aging is the single most …
disability and mortality in later life. As with many chronic conditions, aging is the single most …
[HTML][HTML] The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases
The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating
the innate immune system and inflammatory signaling. Upon activation by PAMPs and …
the innate immune system and inflammatory signaling. Upon activation by PAMPs and …
[HTML][HTML] The impact of disease comorbidities in Alzheimer's disease
JA Santiago, JA Potashkin - Frontiers in aging neuroscience, 2021 - frontiersin.org
A wide range of comorbid diseases is associated with Alzheimer's disease (AD), the most
common neurodegenerative disease worldwide. Evidence from clinical and molecular …
common neurodegenerative disease worldwide. Evidence from clinical and molecular …
The intestinal barrier in disorders of the central nervous system
C Pellegrini, M Fornai, V D'Antongiovanni… - The lancet …, 2023 - thelancet.com
The intestinal barrier, which primarily consists of a mucus layer, an epithelial barrier, and a
gut vascular barrier, has a crucial role in health and disease by facilitating nutrient …
gut vascular barrier, has a crucial role in health and disease by facilitating nutrient …
The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimer's disease
Highlights•Host-derived molecules (eg β-amyloid, tau) trigger NLRP3 inflammasome
signaling.•TNF, ATP, serum amyloid A and the microbiome regulate NLRP3 inflammasome …
signaling.•TNF, ATP, serum amyloid A and the microbiome regulate NLRP3 inflammasome …
The IL-1 family cytokines and receptors in autoimmune diseases
P Migliorini, P Italiani, F Pratesi, I Puxeddu… - Autoimmunity …, 2020 - Elsevier
The role of the cytokines and receptors of the IL-1 family in inflammation is well known.
Several cytokines of the family have a powerful inflammatory activity, with IL-1β being the …
Several cytokines of the family have a powerful inflammatory activity, with IL-1β being the …
[HTML][HTML] Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review
JC Park, SH Han, I Mook-Jung - BMB reports, 2020 - ncbi.nlm.nih.gov
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by the
accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD …
accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD …
[HTML][HTML] What is IL-1 for? The functions of interleukin-1 across evolution
D Boraschi - Frontiers in immunology, 2022 - frontiersin.org
Interleukin-1 is a cytokine with potent inflammatory and immune-amplifying effects, mainly
produced by macrophages during defensive reactions. In mammals, IL-1 is a superfamily of …
produced by macrophages during defensive reactions. In mammals, IL-1 is a superfamily of …
[HTML][HTML] NLRP3 inflammasome: a starring role in amyloid-β-and tau-driven pathological events in Alzheimer's disease
M Van Zeller, D Dias, AM Sebastiao… - Journal of Alzheimer's …, 2021 - content.iospress.com
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease commonly
diagnosed among the elderly population. AD is characterized by the loss of synaptic …
diagnosed among the elderly population. AD is characterized by the loss of synaptic …
[HTML][HTML] Alzheimer's disease: Novel targets and investigational drugs for disease modification
JL Cummings, AML Osse, JW Kinney - Drugs, 2023 - Springer
Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …